Unicycive Therapeutics (UNCY) Common Equity (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Common Equity came in at $37.7 million in Q1 2026, up 234.52% YoY from $11.3 million in Q1 2025, and up 24.86% on a QoQ basis from $30.2 million in Q4 2025.
Unicycive Therapeutics (UNCY) Common Equity (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Common Equity data on file, last reported at $37.7 million in Q1 2026.
- Quarterly Common Equity rose 234.52% year-over-year to $37.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.7 million (up 234.52% YoY) and the FY2025 annual result came in at $30.2 million, up 306.37% from the prior year.
- Common Equity rose to $37.7 million in Q1 2026, from $30.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $37.7 million in Q1 2026 to a low of -$27.8 million in Q3 2024.
- A 5-year average of $3.9 million and a median of $4.6 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 489.3% — and 2024, when it sank 911.01%.
- Tracing UNCY's Common Equity over 5 years: stood at -$466000.0 in 2022, then slumped by 717.38% to -$3.8 million in 2023, then jumped by 295.09% to $7.4 million in 2024, then soared by 306.37% to $30.2 million in 2025, then climbed by 24.86% to $37.7 million in 2026.
- The last three Common Equity figures came in at $37.7 million (Q1 2026), $30.2 million (Q4 2025), and $37.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 53.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 53.27 Mn |
| Mar 31, 2026 | 37.70 Mn |
| Dec 31, 2025 | 30.20 Mn |
| Sep 30, 2025 | 37.48 Mn |
| Jun 30, 2025 | 16.43 Mn |
| Mar 31, 2025 | 11.27 Mn |
| Dec 31, 2024 | 7.43 Mn |
| Sep 30, 2024 | -27.85 Mn |
| Jun 30, 2024 | -14.85 Mn |
| Mar 31, 2024 | -24.46 Mn |
| Dec 31, 2023 | -3.81 Mn |
| Sep 30, 2023 | 3.43 Mn |
| Jun 30, 2023 | -19.37 Mn |
| Mar 31, 2023 | -15.08 Mn |
| Dec 31, 2022 | -466,000.00 |
| Sep 30, 2022 | 4.63 Mn |
| Jun 30, 2022 | 9.91 Mn |
| Mar 31, 2022 | 13.24 Mn |
| Dec 31, 2021 | 16.48 Mn |
| Sep 30, 2021 | 19.00 Mn |